A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

NCT01759576 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Insufficiency
Healthy

Interventions

DRUG: Canagliflozin (JNJ-28431754)

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.